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ABSTRACT 
Dendrimers formulations were significantly explored over the last decade for the transdermal drug delivery applications. The ability of transdermal drug 
delivery  systems  (TDDS)  to  deliver  and  maintain  a  constant  therapeutic  concentration  of  drug  offers  a  significant  potential  for  safe  administration  of 
therapeutic agents. The higher level of control possible over the architectural design of dendrimers; their size, shape, branching length/density, and their 
surface  functionality  clearly  distinguish  it  as  unique  and  optimum  carriers  in  TDDS  applications.  In  this  paper  we  have  attempted  to  summarize  the 
applications of dendrimers in the field of transdermal drug delivery by citing numerous investigators over the last decade. 
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INTRODUCTION 
Today about 74% of drugs are taken orally and are found not 
to  be  as  effective  as  desired  to  improve  such  characters 
transdermal  drug  delivery  system  was  emerged.  Drug 
delivery through the skin to achieve a systemic effect of a 
drug  is  commonly  known  as  transdermal  drug  delivery. 
Transdermal drug delivery systems (TDDS) are dosage forms 
involves  drug  transport  to  viable  epidermal  and  or  dermal 
tissues of the skin for local therapeutic effect while a very 
major fraction of drug is transported into the systemic blood 
circulation.  The  adhesive  of  the  transdermal  drug  delivery 
system  is  critical to  the  safety,  efficacy  and  quality  of  the 
product.  Several  important  advantages  of  transdermal  drug 
delivery  are  enhancement  of  therapeutic  efficiency  and 
maintenance of steady plasma level of the drug. Transdermal 
drug  delivery  (TDD),  a noninvasive  method  of  penetrating 
therapeutic  agents  through  the  skin,  has  already 
revolutionized  the  pharmaceutical  industry.  The  ability  of 
transdermal  drug  delivery  systems  (TDDS)  to  deliver  and 
maintain a constant therapeutic concentration of drug offers a 
significant  potential  for  safe  administration  of  therapeutic 
agents. TDDS can provide a steady drug blood concentration 
and thus avoid peaks and valleys in the drug plasma levels, 
which  occur  with  traditional  dosing,  such  as  oral 
administration  and  intravenous  administration.  Also, 
sustained/prolonged delivery of therapeutic agents in TDDS 
can  simplify  the  dosing  schedule  and  minimize  the  pain 
during traditional drug administration
1. Besides, TDDS can 
improve patient compliance and eliminate the hepatic first-
pass effect and chemical degradation in the gastrointestinal 
tract
2.  Additionally,  patients  can  choose  elsewhere  on  the 
skin to conduct the TDDS according to their need because 
skin  is  the largest  and most  easily  accessible  organ  in  the 
body
3. However, transdermal delivery of drugs is limited due 
to the slow rate of transdermal delivery, chiefly attributable 
to the barrier functions of the skin. The outer layer of the skin 
which is served as the first line of defense is composed of 
closely packed dead cells formed by epidermal differentiation 
and  cornification
3.  It  imposes  a  significant  role  on  the 
diffusion path across the membrane. This major challenge in 
TDDS  prevents  this  promising  technology  from  clinical 
practice.  
Only  small  drug  molecules  (<500  Da)  with  optimal 
physicochemical  properties  (log  P-  13)  can  be  passively 
transported  through  SC.  As  a result,  various  chemical  and 
physical enhancement strategies have evolved to expand the 
number  of  drugs  delivered  through  skin
4.  In  this  regard, 
several  chemical  penetration  enhancers  have  been  widely 
investigated
5.  A large number  of  these  chemical  enhancers 
are  small  molecules  that  penetrate  the  skin  in  significant 
amounts and cause skin irritation or irreversibly alter the skin 
barrier. On the other hand, polymeric enhancers due to their 
large molecular size cannot penetrate deep into the skin and 
hence do not cause skin irritation
6 tested a series of linear 
polymeric enhancers and found them to be non-irritating to 
the skin. The present study focuses on evaluating branched 
PAMAM dendrimer polymers as skin penetration enhancers. 
Over the last decade, numerous drug delivery systems have 
been  explored  to  overcome  the  limitation  of  conventional 
dosage  forms.  Novel  formulations  such  as  nanoparticles, 
liposomes,  dendrimers,  and  niosomes  were  developed  to 
enhance  drug  bioavailability  and  to  minimize  adverse 
effects
4,5. Among them dendrimers formulations were widely 
explored in the last decade for drug delivery applications. 
Dendrimer chemistry was  first introduced in 1978 by Fritz 
Vogtle  and  coworkers
7.  In  1985,  Donald  A.Tomalia, 
synthesized the first family of dendrimers
8. Dendrimers are 
hyperbranched  and  monodisperse  three-dimensional 
macromolecules.  Macromolecular  architecture  and  3D 
structure provides a high degree of surface    functionality 
and versatility. The word dendrimer comes from the Greek 
word dendron, meaning ‘tree’, and meros meaning ‘part’. The 
other synonyms terms used for dendrimer are ‘arborols’ and 
‘cascade  molecules’,  but  ‘dendrimer’  is  the  best  establised 
one. Dendrimers are widely used in drug delivery system due 
to  its  narrow  polydispersity  and  nanometer  size  range. 
Dendrimer are large and complex molecules having very well 
defined chemical structures.  
Dendrimers  possess  three  distinguished  architectural 
components, namely a central core which is either a single 
atom  or  an  atomic  group,  generation  in  which  branching 
emanating from the core composed of repeating units, which 
is  radially  in  position  and many  terminal  functional  group 
generally  located  in  the  exterior  of  the 
macromolecule.(Figure-1) 
The  structural  advantages  allow  dendrimers  to  play  an 
important  role  in  the  fields  of  nanotechnology, 
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attractive
9.  Dendrimers  possess  empty  internal  cavities  and 
open conformations (for low-generation dendrimers), which 
helps in make encapsulation of hydrophobic drug molecules. 
The  higher  level  of  control  possible  over  the  architectural 
design  of  dendrimers;  their  size,  shape,  branching 
length/density,  and  their  surface  functionality  clearly 
distinguish these structures as unique and optimum carriers in 
those applications. Recently, more research focused  on the 
application of dendimers in biomedical fields. 
There  are  many  other  approaches  to  enhance  the  drug 
solubility and drug delivery but they are associated with some 
other  limitations  i.e.  colloidal  and  surfactant  based  system 
(micelles,  emulsion  and  liquid  crystal)  have  draw  back 
related to incomplete and premature release of drug because 
of  disruption  of  micellular  structure  on  dilution  with  body 
fluid  below  critical  micelles  concentration
10.  Parenteral 
administrations  of  β-cyclodextrin  produce  nephrotoxicity 
because of formation of β-cyclodextrin- cholesterol complex, 
which  precipitate  in  kidney.  CDS  may  also  cause  sharp 
change and haemolysis of human erythrocytes. Currently the 
most commonly drug delivery system liposomes have limited 
application due to poor stability and difficulty in targeting to 
specific  tissue.  Dendrimers  with  hydrophobic  core  and 
hydrophilic  periphery  have  shown  to  exhibit  unimolecular 
micellar  type  behavior  and  have  container  properties  in 
solution. 
APPLICATIONS OF DENDRIMERS IN 
TRANSDERMAL DRUG DELIVERY SYSTEM 
Dendrimers  in  Transdermal  Drug  Delivery  (TDD),  a 
noninvasive method of penetrating therapeutic agents through 
the  skin,  has  already  revolutionized  the  pharmaceutical 
industry.  The  ability  of  transdermal  drug  delivery  system 
(TDDS)  to  deliver  and  maintain  a  constant  therapeutic 
concentration of drug offers a significant potential for safe 
administration  of  therapeutic  agents.  TDDS  can  provide  a 
steady  drug  blood  concentration  and  thus avoid  peaks  and 
valleys  in  the  drug  plasma  levels,  which  occurs  with 
traditional  dosing,  such  as  oral  administration  and 
intravenous  administration.  Also,  sustained  /  prolonged 
delivery  of  therapeutic  agents  in  TDDS  can  simplify  the 
dosing  schedule  and  minimize  the  pain  during  traditional 
drug administration. TDDS can improve patient compliance 
and  eliminating  the  hepatic  first-pass  and  chemical 
degradation in the gastrointestinal tract. Patients can choose 
elsewhere on the skin to conduct the TDDS according to their 
need because skin is the largest and most easily accessible 
organ in the body. However, Transdermal delivery of drug is 
limited due to the slow rate of transdermal act as effective 
penetration enhancers. The most common method to improve 
drug  penetration  through  the  skin  is  to  use  transdermal 
enhancers.  Various  transdermal  enhancers,  such  as  organic 
solvents, are effective because they can directly react with the 
skin,  and  thus  transiently  increase  their  permeability  but 
induce immune responses in the skin. Therefore, polymeric 
enhancers with hydrophilic and hydrophobic properties have 
attracted  increasing  interest.  PAMAM  dendrimers  can 
improve either the water solubility or stability of hydrophobic 
drugs.  These  materials  with  hydrophilic  outer  shells  and 
hydrophobic  interiors,  which  accord  with  structural 
requirement of polymeric transdermal enhancer, are expected 
to  act  as  effective  penetration  enhancers.  Recently,  several 
researches have investigated the potential of dendrimers in 
the transdermal route of drug administration
11. 
The  transdermal  ability  of  three  types  of  PAMAM 
dendrimers  (G  4-NH2,  G  4  OH,  and  G  4.5  COOH 
dendrimers) had  been  studied
12.  Indomethacin  was  used  as 
the model drug. The result showed that the steady-state flux 
of indomethacin increased linearly with the concentrationof 
all the three PAMAM dendrimers and was the highest with 
cationic G4 PAMAM dendrimers at 0.2% w/v concentration 
by in vitro permeation studies. During conducting the in vivo 
pharmacokinitcs  and  pharmacodynamic  studies, 
indomethacin and dendrimers formulations were applied to 
the shaved abdominal skin of wistar rats, and the blood from 
the  tail  vein  was  collected  at  the  scheduled  time  after 
dendrimers/drug administration. The maximum indomethacin 
concentration  in  the  blood  was  significantly  higher  with 
PAMAM  dendrimers  when  compared  to  pure  drug 
suspension
11. 
Dendrimers have ideal properties which are useful in targeted 
drug-delivery  system.  One  of    the    most    effective    cell-
specific    targeting  agents  delivered  by  dendrimers  is  folic 
acid PAMAM  dendrimers  modified  with carboxymethyl  
PEG5000  surface  chains revealed reasonable drug loading, a 
reduced  release  rate  and  reduced  haemolytic  toxicity 
compared  with  the  non-PEGylated  dendrimer.  A  third-
generation dendritic unimolecular micelle with indomethacin 
entrapped as model drug gives slow  and  sustained  in  vitro  
release,  as  compared  to  cellulose  membrane  
control
39.Controlled  release  of  the  Flurbiprofen could be 
achieved  by  formation  of  complex  with  amine  terminated 
generation 4 (G4)  PAMAM  Dendrimers
13.The  results found 
that  PEG-dendrimers  conjugated  with  encapsulated    drug  
and  sustained  release  of methotrexate  as  compare  to  
unencapsulated drug. 
Dendrimers have found recent applications in novel topical 
and transdermal, providing benefits such as improved drug 
solubilization,  controlled  release,  and  drug-polymer 
conjugates  (pro-drugs).  The  viscosity-  generation-number 
property of a dendrimers solution allows for ease of handling 
of  highly  concentrated  dendrimers  formulations  for  these 
applications.  Dendrimers have  been  shows  to  be  useful  as 
transdermal  and  topical  drug  delivery  systems  for 
nonsteroidal  anti-inflammatory  drugs  (NSAIDS),  antiviral, 
antimicrobial,  anticancer,  or  antihypertensive  drugs. 
PAMAM  dendrimers  have  been  studied  as  carrier 
transdermal systems for the model NSAID. It was found that 
the PAMAM dendrimers-drug formulation showed increased 
transdermal  drug  delivery  compared  with  formulations 
lacking dendrimers.  
DENDRIMERS IN 
INTRAVENOUS/INTRAPERITONEAL/ 
INTRATUMORAL DRUG DELIVERY 
The intravenous route is the rapidest and simplest method for 
delivering  a  drug  into  the  systemic  circulation  (Figure-2). 
However,  poor  water  solubility  of  many  drugs,  especially 
anti-cancer  drugs,  limits  the  application  of  intravenous 
administration  route  in  clinical  trials.  Intravenous 
administration of these drugs results in several side effects, 
such as hemolysis and phlebitis. Much effort has been made 
to  develop  new  formulations  that  are  suitable  for  the 
intravenous route, among which dendrimer-drug formulation 
is  attracting  increasing  interests  as  one  of  the  emerging 
delivery  systems.  It  should  be  indicated  here  that  both 
intraperitoneal and intratumoral administration of anti-cancer 
drugs  can increase  the  exposure  of  cancer  cells  within  the 
peritoneal  cavity  or  directly  to  the  drug  and  minimize 
potential toxic effects to internal organs.  Dendrimers have 
also  proved  themselves  suitable  for  these  unconventional 
administration  routes.  Before  the  proposed  application  of Verma Priyanka et al. IRJP 2012, 3 (11) 
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dendrimers in the intravenous route, it is worth considering 
their  biodistribution  in  the  body  and  takes  care  that  these 
artificial materials  will not induce  unacceptable  toxicity  or 
immunogenicity  because  most  dendrimers  are not intended 
for pharmaceutical use
11.  
DENDRIMERS IN ORAL DRUG DELIVERY 
Oral delivery system has been the dominant route for many 
years because  of its significant advantages. It is by far the 
most  convenient  administration  route  with  good  patient 
compliance,  especially  in  the  patient  opinions.  In  spite  of 
these benefits, defects of oral delivery route are also obvious. 
Oral delivery usually associates with immediate release of the 
drug and hence causes toxicity in practice. In addition, orally 
administrated  drugs  may  display  low  solubility  in  the 
aqueous  solutions  and  low  penetration  across  intestinal 
membranes. Current strategies to overcome these issues focus 
on several systems in which drugs are loaded into oral drug 
carriers. As the absorption and distribution of drugs in such 
systems  mainly  depended  on  the  properties  of  these 
macromolecular carriers, minimization of the side effects can 
be achieved by modification of the macromolecules structure. 
An  ideal  macromolecular  carrier  for  orally  administrated 
drugs  should  have  the  ability  to  protect  the  drugs  from 
degrading. They might reduce nonspecific interactions with 
food  proteins  and  allow  enhanced  absorption  across  the 
intestinal  epithelium.  Dendrimers  with  featured  properties 
may act as potential candidates for orally controlled release 
systems  by  conjugating/encapsulating  drug  molecules  in 
them.  They  allow  the  maintenance  of  drug  concentrations 
within the therapeutic range at the injured regions, and hence 
can simplify dosing schedules. In addition, dendrimers can 
significantly  increase  the  solubility  of  these  orally 
administrated  drugs  and  even  the  stability  of  drugs  in 
biological  environments.  These  macromolecules  with 
bioadhesive properties have strong affinity  for mucosa and 
can  prolong the  residence  time  of  the  orally  administrated 
drug in contact with the intestinal epithelium. Furthermore, 
dendrimers themselves can easily penetrate through intestinal 
membranes, and thus can enhance the oral absorption of low-
penetration drugs. These properties make dendrimers suitable 
carriers for the development of oral drug delivery systems. 
 It  was  suggested  that  colloidal  drug  carriers  such  as 
dendrimers could be absorbed by way of the Payer’s patches, 
which  is  a  route  to  enhance  the  oral  absorption  of 
encapsulated  drug  molecules  and  to  minimize  enzymatic 
degradation  in  the  intestine  tissue.  Experimental  results 
showed  a  preferential  uptake  of  dendrimers  through  the 
lymphoid  tissue  in  the  small  intestine  but  not  in  the large 
intestine.  These  results  indicated  that  dendrimers  were 
capable to enhance the absorption of low-penetration drugs in 
the small intestine tissues. 
Oral  drug  delivery  studies  using  the  human  colon  
adenocarcinoma  cell  line, Caco-2, have indicated that low-
generation PAMAM dendrimers   cross  cell  membranes, 
presumably  through a combination of  two processes,  i.e. 
paracellular    transport    and  adsorptive    endocytosis. 
Remarkably, the P- gp  efflux  transporter  does  not  appear  
to  affect  dendrimers,  therefore  drug  dendrimer  complexes  
are  able  to  bypass  the  efflux transporter
14. As increase in 
the concentration and generation, there was and methotrexate. 
PAMAM  dendrimers  conjugated  with  the  folic  acid  and 
fluorescein  isothiocyanate for targeting the tumor cells and 
imaging respectively. DNA-assembled dendrimer conjugates 
may allow the combination of different drugs with different 
targeting  and  imaging  agents  so  it  is  easy  to  develop 
combinatorial therapeutics
15. 
Studies  on  Caco-2  monolayers,  as  models  of  intestinal 
epithelial barrier, show that by engineering surface chemistry 
of PAMAM dendrimers, it is possible to minimize toxicity 
while maximizing transepithelial transport
16. 
Duncan and her research  group  systematically  investigated 
the  effect  of  dendrimer  size,  charge,  and  concentration  on 
uptake by the adult rat intestine and studied the absorption 
mechanisms  of  dendrimers  in  intestine  tissues  so  as  to 
develop PAMAM dendrimers as potential oral drug carriers. 
It  was  suggested  that  dendrimer  size  was  a  key  factor  on 
determining overall uptake. Macromolecules with diameters 
up to 3 nm may penetrate through the intestinal membranes 
via either the transcellular or paracellular pathway. Therefore, 
G 2.5 and G 3.5 PAMAM dendrimers could transport across 
the  intestine  via  these  ways.  On  the  other  hand,  G  4  and 
higher  generation  PAMAM  dendrimers  could  attach  to  the 
invigilating plasma membrane, and enter cells by specific or 
nonspecific  adsorptive  endocytosis.  G  2.5  and  G  3.5 
PAMAM dendrimers showed particularly low tissue uptake 
ability, while G5.5 PAMAM dendrimers displayed a higher 
tissue  accumulation  than  G  2.5  and  G  3.5  dendrimers. 
Moreover  cationic  dendrimers  showed a different pattern of 
accumulation  from  anionic  dendrimers.  The  negatively 
charged cell membrane could interact strongly with cationic 
molecules,  and  hence  led  to  higher  tissue  association  and 
lower  transport  rate  of  these  dendrimers.  These  results 
indicated  that  dendrimers  exhibited  a 
size/conformation/charge  sensitivity  of  the  transport 
mechanism across the intestine
11. 
DENDRIMERS IN OCULAR DRUG DELIVERY 
Ideal  ocular  drug-delivery  systems  should  be  nonirritating, 
sterile, isotonic, and biocompatible, does not run out from the 
eye and biodegradable
17.The main challenge in ocular drug 
delivery is to increase the drug bioavailability and prolong 
the residence time of the drug on the cornea, conjunctival, 
and  corneal  epithelia.  Up  to  now,  different  polymeric 
formulations,  such  as  natural  polymers,  bioadhesive 
polymers,  and  colloidal  formulations  have  been  used  as 
potential  ophthalmic  drug  carriers.  These  polymeric 
formulations  with  perfect  viscosity  can  prolong  the  drugs 
residence  time  on  the  cornea  and  increase  their 
bioavailability. However, most of these formulations give rise 
to unwanted side effects. Polymeric nanoparticles tend to be 
removed by lachrymal drainage whereas micro particulates of 
larger  sizes  are  less  tolerable  because  they  may  cause  eye 
irritation and tend to be eliminated by the flow of tears. These 
surface-modified  dendrimers  were  predicted  to  enhance 
pilocarpine  bioavailability
17,  18.  Additionally,  administration 
of these polymers to the cornea may lead to blurred vision 
resulting from infiltration of the lachrymal gland with round 
cells  and  reduced  secretion  of  lachrymal  fluid.  Overall, 
development  of  new  functional  materials  to  avoid  these 
problems  still  holds  the  key  for  the  future  ocular  drug 
delivery. Recently, dendrimers with distinct properties from 
traditional  polymers  were  suggested  to  act  as  ophthalmic 
vehicles in ocular delivery systems. These dendritic polymers 
might dissolve hydrophobic drugs. 
DENDRIMERS IN GENE TRANSFECTION 
The use of dendrimers as gene transfection agents and drug 
delivery  devices  has  been  thoroughly  reviewed  very 
recently
19,  20-22.  Therefore,  only  a  few  highlights  are 
summarized  together  with  additional  recent  studies. 
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delivery  of  DNA  and  small  organic  molecule  drugs, 
especially for cancer therapy. 
Numerous reports have been published describing theuse of 
amino-terminated PAMAM or PPI dendrimers as non-viral 
gene transfer agents, enhancing the transfection of DNA by 
endocytosis  and,  ultimately,  into  the  cell  nucleus
23,24-33.  It 
should be noted that dendrimers of high structural flexibility 
and  partially  degraded  high-generation  dendrimers  (i.e., 
hyperbranched  architectures)  appear  to  be  better  suited  for 
certain gene delivery operations than intact high-generation 
symmetrical dendrimers. Perhaps this is due to their enhanced 
flexibility,  which  allows  the  formation  of  more  compact 
complexes  with  DNA
34,  35.  Furthermore,  it has  been  found 
that maximum transfection efficiency is obtained with a net 
positive charge on the complexes (i.e., an excess of primary 
amines over DNA phosphates). 
 
 
Figure 1: Structure of dendrimers 
 
 
Figure 2:  Potential pharmacokinetics of (A) Traditional dosing, (B) Formulations of drug/dendrimer complexes, and (C) Drug–dendrimer 
conjugates. 
 
CONCLUSION 
Numerous  applications  of  dendrimer  in  transdermal  drug 
delivery  were  extensively  studied.  These  carriers  have 
successfully improved the drug bioavailability by controlled 
and  targeted  delivery.  The  high  level  of  control  over  the 
architecture of dendrimer, their shape, branching length and 
density,  and  their  surface  functionality,  makes  dendrimer 
ideal carriers for the various applications like drug delivery, 
therapeutic and  diagnostic agent.  So  all this  studies at  last 
concluded that dendrimers is successfully used in application 
of transdermal drug delivery system.  
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